Abstract
FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 489-494 |
| Number of pages | 6 |
| Journal | Best Practice and Research: Clinical Haematology |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2010 |
Keywords
- AC220
- AML
- Acute myeloid leukemia
- FLT3
- Inhibitor
- KW-2449
- Lestaurtinib
- Midostaurin
- Sorafenib
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry